Are IDH2 Inhibitors Right for Your AML Patient?
Please complete Pre-test
Chapter 1 of 3
Release Date: May 15, 2018
Expiration Date: May 15, 2019
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The treatment landscape for acute myeloid leukemia (AML) continues to evolve with several recent FDA approvals of novel treatment options, including an isocitrate dehydrogenase 2 (IDH2) inhibitor. Mutated IDH2 is present in 8-19% of patients diagnosed with AML, making it an important target to treat when managing the disease. View this activity and hear how Dr. Carraway discusses the role of IDH2 inhibitors in the diagnosis, prognosis, and treatment of patients with IDH2-mutated AML. She will outline a treatment plan for managing these patients in the relapsed or refractory setting, taking into consideration patient selection, proper administration, and potential adverse events. Furthermore, Dr. Carraway will identify the latest updates in emerging data related to the safety and efficacy of IDH2 inhibitors currently in clinical trials.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with AML.
Upon completion of this educational activity, participants should be able to:
- Summarize the role of IDH2 inhibitors in the diagnosis, prognosis, and treatment of patients with IDH-mutated AML
- Outline a treatment plan for patients demonstrating an IDH-2 mutation in the relapsed or refractory setting, taking into consideration patient selection, proper administration, and potential adverse events
- Identify the latest updates on emerging data related to safety and efficacy of IDH2 inhibitors currently in clinical trial
Are IDH2 Inhibitors Right for Your AML Patient? - Hetty E. Carraway, MD
Instructions for Participation and Credit
This activity is eligible for credit through May 15, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Hetty E. Carraway, MD
Hematologic Oncology and Blood Disorders
Taussig Cancer Institute, Cleveland Clinic
Dr. Hetty Caraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her fellowship in medical oncology at Johns Hopkins University in Baltimore. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is currently a Staff Physician at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic.
Dr. Carraway is American Board of Internal Medicine certified in medical oncology and internal medicine. She is a member of numerous professional organizations including the American Society of Hematology (ASH), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Eastern Cooperative Oncology Group (ECOG), SWOG, and the America College of Physicians, among others. Dr. Carraway has co-authored numerous peer-reviewed publications, review articles, editorials, abstracts and book chapters. She is nationally sought for her expertise in hematologic malignancies. As a translational clinical scientist, Dr. Carraway’s research is focused on experimental therapeutics of acute leukemias and myeloproliferative diseases.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., and Helsinn Healthcare SA.
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-006-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Hetty Carraway has received honoraria related to formal advisory activities from Agios and Celgene Corporation; and speakers’ bureau activities from Agios, Baxalta, Celgene, Jazz Pharmaceuticals plc, Novartis AG, and Shire. She has received grant support related to research activities from Celgene.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.